Neuroprotective Peptides — Cerebrolysin, Semax, Selank & More

How research peptides protect the brain, enhance neuroplasticity, and support cognitive recovery — the compounds, mechanisms, evidence, and practical considerations.

Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Most compounds discussed are research peptides not approved for human use in the US. Neurological conditions require professional medical management. Always consult a qualified healthcare professional.

The brain is arguably the most vulnerable organ in the body — it consumes 20% of total energy while comprising only 2% of body weight, it has limited regenerative capacity compared to other tissues, and it is susceptible to a wide range of insults including oxidative stress, inflammation, ischemia, and physical trauma. Neuroprotective compounds help shield neurons from these threats and support the brain's own repair mechanisms.

Several research peptides have demonstrated neuroprotective properties in preclinical and clinical studies. Cerebrolysin is used clinically in over 40 countries for stroke and dementia. Semax and Selank are approved medications in Russia. Dihexa shows extraordinary potency in preclinical synaptogenesis models. And even the healing peptide BPC-157 has demonstrated neuroprotective effects.

This guide examines the mechanisms, evidence, and practical applications of neuroprotective peptides. For cognitive enhancement in healthy brains, see our nootropics guide and best peptides for brain health roundup.

Key Mechanisms of Neuroprotection

Neuroprotective peptides work through several interconnected mechanisms that protect existing neurons and support brain repair:

Neurotrophic Factor Enhancement

BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) are proteins critical for neuron survival, growth, and connection strength. BDNF is particularly important for synaptic plasticity — the ability to strengthen or weaken neural connections in response to experience (the biological basis of learning and memory). Multiple neuroprotective peptides — especially Semax and Cerebrolysin — work by upregulating BDNF and NGF expression.

Anti-Neuroinflammation

Chronic neuroinflammation — driven by activated microglia (the brain's immune cells) — is implicated in virtually every neurodegenerative condition. Peptides like Selank and BPC-157 modulate neuroinflammatory pathways, reducing the damaging chronic activation while preserving the beneficial acute inflammatory response needed for repair.

Synaptogenesis & Neuroplasticity

Synaptogenesis — the formation of new synaptic connections — is essential for cognitive recovery after injury and for maintaining cognitive function with aging. Dihexa has shown remarkable potency in promoting synaptogenesis (millions of times more potent than BDNF in cell culture models). Cerebrolysin also supports synaptic density and dendritic branching.

Anti-Apoptotic Protection

During ischemic events (stroke, TBI), neurons can be pushed into apoptosis (programmed cell death). Several neuroprotective peptides activate anti-apoptotic pathways (like Bcl-2 upregulation and caspase inhibition) that keep neurons alive during and after these insults. This is the primary clinical application of Cerebrolysin in acute stroke management.

The Major Neuroprotective Peptides

Cerebrolysin

Cerebrolysin is the most clinically validated neuroprotective peptide compound. It consists of a standardized mixture of neuropeptides and amino acids derived from porcine brain tissue, processed to contain only low-molecular-weight fragments that cross the blood-brain barrier. Clinical trials have demonstrated benefits in acute ischemic stroke (improved functional recovery when administered within 72 hours), Alzheimer's disease (improved cognitive scores on ADAS-cog), vascular dementia, and traumatic brain injury. It is administered via IM or IV injection in clinical settings, typically in 10-20 day treatment courses. It is a prescription medication in over 40 countries but is not FDA-approved in the US.

Semax

Semax is a synthetic heptapeptide derived from the N-terminal fragment of ACTH (adrenocorticotropic hormone). Developed in Russia, it is approved there for the treatment of stroke, cognitive disorders, and peptic ulcers. Its neuroprotective effects include significant BDNF upregulation, enhanced attention and cognitive processing speed, neuroprotective effects against oxidative stress, and improved cerebral blood flow. It is administered as an intranasal spray (200-600mcg per day in 2-3 doses), which provides direct access to the CNS. See our Selank vs Semax comparison and Dihexa vs Cerebrolysin comparison.

Selank

Selank is a synthetic analogue of the immunomodulatory peptide tuftsin. Also developed and approved in Russia, it has anxiolytic (anti-anxiety) and nootropic properties. Its neuroprotective mechanisms include GABA receptor modulation (anxiolytic effect without sedation), enhanced BDNF expression, anti-neuroinflammatory effects, and serotonin metabolism modulation. It is particularly valuable for people whose cognitive impairment is anxiety-driven. Administered as an intranasal spray at 250-500mcg 2-3x daily.

Dihexa

Dihexa is a research peptide that activates hepatocyte growth factor (HGF/c-Met) signaling in the brain. In preclinical studies, it demonstrated extraordinary potency in promoting synaptic connectivity — described as up to 10 million times more potent than BDNF in cell-based synaptogenesis assays. It enhanced cognitive function in animal models of Alzheimer's disease and cognitive aging. However, it is a very early-stage research compound with minimal safety data, and its extreme potency warrants caution. Administered SubQ or intranasally.

BPC-157

BPC-157, primarily known as a healing peptide, has demonstrated significant neuroprotective effects in animal models. It protects against NSAID-induced brain lesions, reduces brain edema after traumatic injury, modulates dopaminergic and serotonergic systems, and promotes neuronal survival. Its GH receptor upregulation may also contribute to neuroprotection via increased IGF-1 signaling. See our BPC-157 vs TB-500 comparison.

Clinical and Research Applications

Stroke recovery: Cerebrolysin has the strongest clinical evidence, with multiple randomized controlled trials showing improved functional outcomes when administered within 72 hours of acute ischemic stroke. Semax also has Russian clinical data for post-stroke recovery.
Traumatic brain injury (TBI): Cerebrolysin has shown benefits in moderate-severe TBI. BPC-157 has preclinical neuroprotective data. These compounds may support recovery when used adjunctively with standard medical care.
Neurodegenerative diseases: Cerebrolysin has moderate clinical evidence for Alzheimer's disease. Dihexa's HGF activation is being studied for its potential in neurodegenerative conditions. These are adjunctive approaches, not replacements for standard treatments.
Cognitive aging: Age-related cognitive decline involves progressive loss of synaptic density and neurotrophic factor production. Peptides that enhance BDNF (Semax), promote synaptogenesis (Dihexa), and support neuroplasticity (Cerebrolysin) are being explored for healthy brain aging.
Anxiety-related cognitive impairment: Selank's combined anxiolytic and nootropic effects make it particularly relevant for people whose cognitive performance is impaired by anxiety, stress, or GABAergic dysregulation.

Practical Considerations & Safety

Neuroprotective peptides span a wide range of evidence levels and risk profiles:

Cerebrolysin has the most extensive safety and efficacy data. It is a regulated pharmaceutical in many countries. Side effects are generally mild (headache, dizziness). It requires clinical administration (IM/IV).
Semax and Selank are approved medications in Russia with established safety profiles. Intranasal administration makes them accessible and easy to use. Side effects are minimal at recommended doses.
Dihexa has the least safety data and should be approached with the most caution. Its extreme potency is a double-edged sword — insufficient data exists to characterize long-term risks of such potent synaptogenic activity.
BPC-157 has extensive preclinical safety data and a wide safety margin in animal studies, but limited human clinical trials specifically for neuroprotection.

For general peptide safety information, see our peptide safety guide. For administration details, see our how to use peptides guide. Neuroprotective applications — especially for acute conditions like stroke or TBI — should always be managed by a neurologist or qualified physician.

Key Takeaways

Neuroprotective peptides protect neurons through BDNF/NGF enhancement, anti-inflammatory effects, synaptogenesis, and anti-apoptotic pathways.
Cerebrolysin has the most clinical data — approved in 40+ countries for stroke, Alzheimer's, and TBI. The most evidence-backed option.
Semax enhances BDNF and cognition; Selank provides anxiolytic neuroprotection. They pair well together. See Selank vs Semax comparison.
Dihexa is extraordinarily potent but early-stage — approach with caution due to limited safety data.
BPC-157 has unexpected neuroprotective properties beyond its primary healing reputation.
Explore our brain health peptides guide, nootropics guide, and peptide catalog for more on cognitive compounds.

Frequently Asked Questions

What are neuroprotective peptides?

Neuroprotective peptides are compounds that protect neurons from damage, support neural repair, and enhance the brain's resilience against various forms of stress — including oxidative damage, excitotoxicity, inflammation, and ischemia (reduced blood flow). They work primarily by enhancing neurotrophic factor expression (BDNF, NGF, GDNF), supporting neuroplasticity (the brain's ability to form new connections), reducing neuroinflammation, and promoting neurogenesis (birth of new neurons). Examples include Cerebrolysin, Semax, Selank, Dihexa, and BPC-157.

What is Cerebrolysin and how is it used?

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue. It is one of the most clinically studied neuroprotective peptides, with clinical trials in stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia. It is approved as a prescription medication in over 40 countries (not in the US). It is administered via intramuscular or intravenous injection, typically 5-30mL daily for 10-20 day courses. It enhances BDNF, reduces neuroinflammation, and supports synaptic plasticity.

Is Semax or Selank better for brain health?

They serve complementary purposes. Semax is more stimulating and cognitively enhancing — it increases BDNF expression, improves attention and memory, and has a nootropic-energizing quality. It is better for focus, learning, and active cognitive performance. Selank is more anxiolytic and calming — it enhances GABA activity, reduces anxiety, and improves cognitive function specifically impaired by stress. It is better for people whose cognitive issues are anxiety-related. Many users combine both — Semax in the morning for focus, Selank in the afternoon or evening for anxiolytic clarity.

Can peptides help with traumatic brain injury (TBI)?

Several peptides have shown promise for TBI recovery in preclinical and clinical research. Cerebrolysin has the most clinical trial data — multiple studies show improved cognitive recovery and functional outcomes in TBI patients. BPC-157 has demonstrated neuroprotective effects in animal models of brain injury, including reduction of brain edema and improved behavioral recovery. Semax has clinical data from Russia for post-stroke cognitive recovery. Dihexa shows potent synaptogenic activity in preclinical models. However, TBI treatment should always be managed by a neurologist.

How do neuroprotective peptides differ from nootropics?

Nootropics enhance cognitive performance in healthy brains — they make a normally functioning brain work better. Neuroprotective peptides protect brain cells from damage, support repair after injury, and enhance the brain's structural resilience. There is significant overlap — Semax and Selank are both nootropic and neuroprotective. The distinction matters for application: if you want sharper focus for a work project, that is nootropic use. If you want to protect your brain long-term, recover from a concussion, or slow cognitive aging, that is neuroprotection. Many peptides serve both purposes.

Are neuroprotective peptides safe for long-term use?

Safety data varies by compound. Cerebrolysin has the most extensive safety record — it has been used clinically for decades in multiple countries with a favorable safety profile. Semax and Selank are approved medications in Russia with established safety records for their approved uses. Dihexa has very limited safety data and should be approached with caution. BPC-157 has extensive animal safety data but limited human clinical trials specifically for neuroprotection. Long-term use of any peptide should be discussed with a healthcare professional who can monitor for potential effects.